Biocon joins hands with US company Amylin for diabetes drug

14 Sep 2009 Evaluate

Biocon has put the development of its diabetes drug on the fast track by teaming up with US-based biopharma player Amylin Pharmaceuticals. The companies have entered into an exclusive co-development and marketing partnership for a peptide hybrid or phybrid. This phybrid will combine properties of two peptides — essentially small proteins — into one molecule to treat diabetes. For instance, this bi-functionality could lower glucose levels as well as induce weight loss.

Against using single properties on their own, this technology is likely to give a differentiated clinical outcome by enabling the interplay of two peptides with dual benefits (like lower sugar level and weight loss).

Amylin Pharmaceuticals has been a front-runner in the field of peptide therapeutics and a leader in the diabetes market. The Kiran Mazumdar Shaw-led Biocon will in turn bring its recombinant knowledge, large-scale manufacturing and low-cost pre-clinical and clinical development to the partnership.

crackcrack

Biocon Share Price

320.00 -0.65 (-0.20%)
29-Apr-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.80
Dr. Reddys Lab 1176.25
Cipla 1543.45
Lupin 2076.90
Zydus Lifesciences 887.95
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...